UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

Benzinga · 2d ago
UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.